Arch Therapeutics, Inc. (ARTH)
USD 0.23
(31.81%)
USD 0.23
(31.81%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.87 Million USD | 74.62% |
| 2022 | 3.36 Million USD | 110.14% |
| 2021 | 1.6 Million USD | 120.29% |
| 2020 | 726.3 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 977.88 Thousand USD | -32.12% |
| 2015 | 1.44 Million USD | 50.72% |
| 2014 | 955.76 Thousand USD | 1.17% |
| 2013 | 944.7 Thousand USD | -53.0% |
| 2012 | 2.01 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 7.28 Million USD | 24.04% |
| 2024 Q3 | 9.38 Million USD | 16.51% |
| 2024 Q2 | 8.05 Million USD | 10.65% |
| 2023 Q1 | 3.75 Million USD | 11.65% |
| 2023 Q4 | 5.87 Million USD | 89.9% |
| 2023 FY | 5.87 Million USD | 74.62% |
| 2023 Q3 | 3.09 Million USD | 56.04% |
| 2023 Q2 | 1.98 Million USD | -47.22% |
| 2022 Q1 | 1.6 Million USD | 0.0% |
| 2022 FY | 3.36 Million USD | 110.14% |
| 2022 Q4 | 3.36 Million USD | 110.14% |
| 2022 Q2 | 1.6 Million USD | 0.0% |
| 2022 Q3 | 1.6 Million USD | 0.0% |
| 2021 FY | 1.6 Million USD | 120.29% |
| 2021 Q1 | 1.77 Million USD | 144.57% |
| 2021 Q2 | 1.77 Million USD | 0.0% |
| 2021 Q3 | 1.6 Million USD | -9.93% |
| 2021 Q4 | 1.6 Million USD | 0.0% |
| 2020 Q4 | 726.3 Thousand USD | 0.0% |
| 2020 FY | 726.3 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q3 | 726.3 Thousand USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | -100.0% |
| 2017 Q1 | 754.81 Thousand USD | -22.81% |
| 2016 FY | 977.88 Thousand USD | -32.12% |
| 2016 Q4 | 977.88 Thousand USD | 0.28% |
| 2016 Q1 | 1.23 Million USD | -14.24% |
| 2016 Q3 | 975.11 Thousand USD | -9.07% |
| 2016 Q2 | 1.07 Million USD | -13.2% |
| 2015 Q3 | 1.46 Million USD | 6.67% |
| 2015 Q1 | 958.53 Thousand USD | 0.29% |
| 2015 FY | 1.44 Million USD | 50.72% |
| 2015 Q4 | 1.44 Million USD | -1.51% |
| 2015 Q2 | 1.37 Million USD | 43.04% |
| 2014 Q4 | 955.76 Thousand USD | 0.29% |
| 2014 FY | 955.76 Thousand USD | 1.17% |
| 2014 Q3 | 953 Thousand USD | 0.29% |
| 2014 Q2 | 950.23 Thousand USD | 0.29% |
| 2014 Q1 | 947.47 Thousand USD | 0.29% |
| 2013 Q1 | 61.00 USD | -100.0% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q4 | 944.7 Thousand USD | 0.0% |
| 2013 Q2 | 2.26 Million USD | 3705145.9% |
| 2013 FY | 944.7 Thousand USD | -53.0% |
| 2012 FY | 2.01 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | 2.01 Million USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 85.751% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -42.435% |
| SQZ Biotechnologies Company | 27.47 Million USD | 78.628% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 86.464% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 80.277% |
| Mesoblast Limited | 118.7 Million USD | 95.054% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -519.136% |
| Genus plc | 233.1 Million USD | 97.481% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -100.352% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -336.972% |
| Marizyme, Inc. | 18.71 Million USD | 68.633% |
| ContraFect Corporation | 2.88 Million USD | -103.787% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -682.812% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -4233.323% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -305.933% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -152.416% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -3.76% |
| MultiCell Technologies, Inc. | 202.58 USD | -2898058.752% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 89.787% |
| EV Biologics, Inc. | 1.49 Million USD | -292.78% |
| Q BioMed Inc. | 4.1 Million USD | -42.85% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 82.263% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -831.805% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -377.961% |
| Biomind Labs Inc. | 735.54 Thousand USD | -698.199% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 96.578% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 54.827% |
| Skye Bioscience, Inc. | 4.61 Million USD | -27.21% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -561.111% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -4048.652% |
| IMV Inc. | 28.88 Million USD | 79.673% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -22727.832% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -159.969% |
| GB Sciences, Inc. | 1.75 Million USD | -233.716% |
| Alpha Cognition Inc. | 1.22 Million USD | -381.09% |
| HST Global, Inc. | 98.31 Thousand USD | -5871.47% |
| CSL Limited | 12.18 Billion USD | 99.952% |
| Halberd Corporation | 150 Thousand USD | -3814.06% |
| Enzolytics Inc. | 996.33 Thousand USD | -489.267% |
| Resverlogix Corp. | 6.49 Million USD | 9.55% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1129.548% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -2197.055% |
| argenx SE | 20 Million USD | 70.645% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 87.113% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -116.749% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -57318.973% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.595% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2826.531% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -144.861% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2460.541% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 91.32% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -94.009% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1532.173% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 71.118% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3849.5% |
| BioStem Technologies, Inc. | 4.71 Million USD | -24.614% |
| ONE Bio Corp. | 19.71 Million USD | 70.22% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -2246.728% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -2260.522% |
| Agentix Corp. | 50 Thousand USD | -11642.18% |
| LadRx Corporation | 33.6 Thousand USD | -17370.362% |
| Cell Source, Inc. | 9.25 Million USD | 36.557% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -676.39% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -676.39% |
| NovAccess Global Inc. | 2.19 Million USD | -166.882% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 16.991% |
| Itoco Inc. | 228.37 Thousand USD | -2470.789% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2682.837% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -17.822% |
| Kadimastem Ltd | 891.22 Thousand USD | -558.766% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1361.019% |
| CytoDyn Inc. | 30.07 Million USD | 80.479% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1112.324% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1568.649% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 24.922% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -4692.727% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1793.9% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -23.986% |
| International Stem Cell Corporation | 4.17 Million USD | -40.524% |
| Bioxytran, Inc. | 1.92 Million USD | -204.992% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -9306.838% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -169.205% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 29.4% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 31.612% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -277.446% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2090.705% |
| Neutra Corp. | 54.15 Thousand USD | -10741.07% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -220.825% |
| PureTech Health plc | 25.51 Million USD | 76.987% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -379.576% |
| IXICO plc | 472.02 Thousand USD | -1143.814% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 62.124% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 90.57% |
| CSL Limited | 12.18 Billion USD | 99.952% |
| Cellectis S.A. | 92.77 Million USD | 93.672% |